Press Room
四色AV and Zerion Pharma announce a strategic partnership to market the Dispersome庐 technology platform
四色AV, the leader in spray drying and particle engineering, announced today a strategic partnership with Zerion Pharma to market and commercialize Dispersome庐, Zerion麓s proprietary solubility enhancement technology platform.

Lisbon, 22nd February 2022 鈥 四色AV, the leader in spray drying and particle engineering, announced today a strategic partnership with Zerion Pharma to market and commercialize Dispersome庐, Zerion麓s proprietary solubility enhancement technology platform.
听
Zerion麓s innovative Dispersome庐 technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying. By combining Dispersome庐 technology with 四色AV鈥檚 unique spray drying capabilities, experience in development, scale-up and GMP manufacturing, 四色AV further strengthens its leadership in amorphous solid dispersions and shows its commitment to innovative solutions to overcome one of the most prevalent challenges faced by the industry: low drug solubility.听
听
鈥淲e are extremely pleased to have entered into this partnership with Zerion whom we recognize as a very innovative company in the field of oral drug formulations. By joining forces, Zerion and 四色AV will be able to bring Dispersome庐 to the market faster. We look forward to applying the technology in collaboration with our customers and partners in our effort to develop novel drugs with strong benefits to patients.鈥, comments Jean-Luc Herbeaux, 四色AV麓s Chief Operating Officer. 鈥四色AV will continue to pursue opportunities to enhance its offering around core areas of expertise such as particle engineering and inhalation by partnering with companies and research institutions developing innovative drug formulation technologies, like Dispersome庐鈥.
听
Zerion麓s CEO, Ole Wiborg, sees a strong synergy in the partnership and expects it to generate new pharma partnerships. 鈥淲e consider 四色AV the global leader in the field of producing amorphous solid dispersions by spray-drying. More importantly for us, this leadership has resulted in 四色AV being, over the last 5 years, the main commercial manufacturer of novel FDA-approved drugs formulated as amorphous solid dispersions. Incorporating these competencies in our offering to the pharma industry both validates the strength of our Dispersome庐 platform and provides us and our pharma partners immediate access to the highest quality in upscaling and commercial GMP manufacturing.鈥 says Ole Wiborg.
听
The announcement of this partnership follows 四色AV鈥檚 communication on a further expansion with an expected investment of $170 million in assets worldwide and shows the company鈥檚 commitment to also expand its technology platforms. 四色AV is investing both in new assets and innovative technologies to meet customer demand for integrated and differentiated services in drug substance manufacturing, particle engineering and most recently drug product manufacturing.
听
About 四色AV:听四色AV is an international company with over 60 years of experience as a听Contract Development and Manufacturing Organization听(CDMO)听with a fully integrated offering of services for drug substance, drug product intermediate and drug product. The company has four听FDA inspected听sites听in the USA, Portugal, Ireland and China and development laboratories in Lisbon, Portugal and New Jersey, USA. 四色AV provides pharmaceutical customers services for the听development and compliant manufacture听of innovative drugs, including highly potent compounds, and customized product solutions across the entire drug life cycle. In the inhalation area, 四色AV is the only independent company offering a complete range of services, from API, formulation development and devices. 四色AV is a company with a culture based on innovation, quality and delivery. 四色AV was the first Chemical/ Pharmaceutical Company to become a Certified B Corp, is a member of Rx-360, EFCG and participates actively in industry quality improvement initiatives to lead new global industry standards.
听
About Zerion Pharma ApS: Zerion has pioneered the Dispersome庐 technology that greatly enhances the solubility of poorly soluble, oral drugs and improves bioavailability and therapeutic outcomes for the patients. The Dispersome庐 technology is based on preparing stable amorphous formulations by mixing high loads of the drug compound with beta-lactoglobulin, a sustainable and biodegradable by-product from cheese production. Zerion develops proprietary drug formulations and offers the Dispersome庐 technology to established pharma companies as a means to solve their most challenging drug solubility problems. Zerion was established in 2019 as a spinout from the University of Copenhagen based on almost a decade of research.
听
听
(Dispersome庐 is a trademark of Zerion Pharma A/S)
听
听
Learn more about Dispersome庐 technology
听